Overview
- TrumpRx, a federal purchasing site launching in January, will steer consumers to Wegovy and Zepbound offers near $350 per month with a target of about $245 within two years, according to reporting.
- Novo Nordisk said lowest-dose Wegovy would be $149 per month if approved and confirmed plans to lower prices for Wegovy and Ozempic across Medicare, Medicaid and self-pay channels.
- Eli Lilly said self-pay Zepbound will range from $299 to $449 depending on dose, with its once-daily oral orforglipron targeted to start at $149 for the lowest dose if it wins federal approval, and it plans 50%–60% list-price cuts for additional medicines on LillyDirect.
- The administration says Medicare coverage for obesity treatment will expand next year, with Fox Business reporting a $50 monthly cap for beneficiaries on Zepbound and orforglipron.
- Dr. Mehmet Oz, who leads Medicare and Medicaid Services, predicted oral weight-loss pills will replace injections by March 2026, while a separate State Department memo reportedly instructs consular officers to weigh applicants’ health, including obesity, in visa decisions.